Zacks Investment Research upgraded shares of KemPharm (NASDAQ:KMPH) from a hold rating to a buy rating in a research note issued to investors on Thursday. The firm currently has $7.25 price target on the specialty pharmaceutical company’s stock.
According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “
Several other research analysts have also weighed in on KMPH. Roth Capital set a $10.00 target price on shares of KemPharm and gave the stock a buy rating in a research report on Monday, April 2nd. Oppenheimer set a $13.00 target price on shares of KemPharm and gave the stock a buy rating in a research report on Monday, April 2nd. ValuEngine upgraded shares of KemPharm from a strong sell rating to a sell rating in a research report on Friday, March 9th. Royal Bank of Canada set a $9.00 target price on shares of KemPharm and gave the stock a buy rating in a research report on Tuesday, January 16th. Finally, Canaccord Genuity set a $11.00 target price on shares of KemPharm and gave the stock a buy rating in a research report on Friday, February 23rd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $10.05.
Shares of KMPH opened at $6.28 on Thursday. The company has a current ratio of 7.56, a quick ratio of 7.56 and a debt-to-equity ratio of -1.92. KemPharm has a twelve month low of $2.45 and a twelve month high of $8.40. The stock has a market cap of $94.78, a price-to-earnings ratio of -2.12 and a beta of -0.34.
KemPharm (NASDAQ:KMPH) last issued its earnings results on Thursday, March 29th. The specialty pharmaceutical company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.04). equities analysts anticipate that KemPharm will post -2.59 EPS for the current year.
An institutional investor recently raised its position in KemPharm stock. Alyeska Investment Group L.P. raised its holdings in KemPharm (NASDAQ:KMPH) by 1.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 992,338 shares of the specialty pharmaceutical company’s stock after purchasing an additional 17,721 shares during the period. Alyeska Investment Group L.P. owned 6.77% of KemPharm worth $3,672,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 36.56% of the company’s stock.
TRADEMARK VIOLATION WARNING: “KemPharm (KMPH) Stock Rating Upgraded by Zacks Investment Research” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/09/kempharm-kmph-stock-rating-upgraded-by-zacks-investment-research.html.
KemPharm Company Profile
KemPharm, Inc, a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain.
Get a free copy of the Zacks research report on KemPharm (KMPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.